StockData

Astrana Health vs Huron Consulting

ASTH and HURN side by side, both in management and public relations services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ASTH and HURN compare

Huron Consulting is the larger company, worth 1.5 times as much as Astrana Health ($2.7B against $1.8B).

On earnings, Huron Consulting is cheaper: it trades at 25.5× trailing earnings, against 39.0× for Astrana Health.

Astrana Health grew revenue faster over the last twelve months (58.9% versus 13.6% for Huron Consulting).

Huron Consulting keeps more of each dollar of sales as profit, with a net margin of 6.4% compared with 1.1% at Astrana Health.

Huron Consulting scores higher on the StockData Score (14 against 8 for Astrana Health), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricASTHHURN
Size and price
Market cap$1.8B$2.7B
Share price$31.99$170.33
Change, 1 year48.6%2.9%
Change, 5 years−66.2%258%
Beta (5Y)1.040.65
Employees3,000305
StockData Score
Total score814 (better)
Valuation score11
Growth score45 (better)
Performance score25 (better)
Health score13 (better)
Dividend score00
Valuation
P/E39.0×25.5× (better)
P/S0.5× (better)1.5×
P/B2.1× (better)7.0×
EV/EBITDA14.2× (better)15.6×
P/FCF18.9×16.8× (better)
PEG–1.50
FCF yield5.3%5.9% (better)
Fair value$26.18$153.76
Margin of safety−22.2%−10.8% (better)
Growth
Revenue growth (TTM)58.9% (better)13.6%
Revenue growth, 5Y average35.9% (better)14.3%
Net income growth (TTM)60.5% (better)9.9%
EPS growth (TTM)57.7% (better)16.4%
EPS growth, 5Y average−14.6%–
Profitability
Gross margin10.5%34.0% (better)
Operating margin2.6%10.3% (better)
Net margin1.1%6.4% (better)
FCF margin2.5%8.9% (better)
Return on equity5.1%26.9% (better)
Return on invested capital6.0%12.3% (better)
Financial health
Debt / equity1.13 (better)2.16
Net debt / EBITDA3.28 (better)3.57
Interest coverage1.5×–
Current ratio1.231.71 (better)
Altman Z-score2.773.44 (better)
Piotroski F-score46 (better)
Dividends and buybacks
Payout ratio4.6%–
Buyback yield1.00%8.8% (better)
Shareholder yield1.00%8.8% (better)
Ownership
Held by institutions57.7%99.3%
Held by insiders30.7%2.4%
Insider net buying, 12 months–−$6.4M
Short interest, % of float7.8%4.7%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.